FibroGen, Inc (FGEN) analyst actions
Rating and price-target actions on FGEN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the FGEN overview →
1 measured FGEN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer | Press release | -4.33% | +1.23% |
Keep exploring
More FGEN: earnings → · SEC filings → · FGEN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| Atossa Therapeutics, Inc. (ATOS) | 222 | -0.02% | 48% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.